Facebook
Twitter
LinkedIn
ForwardHigher Dose Buprenorphine
This module reviews the efficacy and effectiveness of prescribing up to 32 milligrams of buprenorphine per day to treat opioid use disorders. After summarizing the history of FDA regulations on the use of buprenorphine, the speaker provides an in-depth review on emerging research and clinical data that support the recent FDA decision to change the dose guidance on prescribing high-dose buprenorphine.
Target Audience
Health care professionals (MD, DO, PA, NP) that do prescribe or want to prescribe buprenorphine
Learning Objectives
Discuss patient-centered goals and clinical criteria for determining buprenorphine dose adequacy.
Describe the history of buprenorphine dose regulation in the United States including the FDA’s recent decision, and how that regulation affects patient care.
Cite examples of pharmacological and clinical research showing dose-dependent benefits of buprenorphine up to at least 32 mg/day
Dr. Lucinda Grande received her medical degree at the University of Washington, completed residency at Providence St. Peter Family Medicine in Olympia, and is a partner at Pioneer Family Practice in Lacey. She provides primary care, specializing in management of chronic pain and opioid use disorder. She is a co-founder and Medical Director of the Olympia Bupe Clinic, a low-barrier buprenorphine clinic for patients with opioid use disorder. She is a Clinical Assistant Professor in the UW Department of Family Medicine. She is an advocate for policy change on behalf of people with substance use disorder and chronic pain.
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Compass Healthcare Collaborative and Colorado Consortium for Prescription Drug Abuse Prevention. Compass Healthcare Collaborative is accredited by the IMS to provide continuing medical education for physicians.
Designation: Compass designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity was developed without support from any ineligible company. *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.
Disclosure: Compass adheres to the Standards for Integrity and Independence in Accredited Continuing Education. The content of this activity is not related to products or the business lines of an ACCME-defined ineligible company. None of the planners or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients.
Available Credit
- 1.00 AMA PRA Category 1 Credit™